文献速递新药、器械与细胞基因治疗研发临床试验与 GCP基础与转化研究

慢病毒基因治疗重型白细胞黏附缺陷症1型

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.
PubMed 文献 · N Engl J Med · 2025-01-01

一项1-2期多国开放标签研究纳入9例重型白细胞黏附缺陷症1型(LAD-I)患儿,给予慢病毒转导自体CD34+造血干细胞(marne-cel)治疗并随访24个月;无基因治疗相关不良事件,无移植物失败,输注后1年无HSCT生存率100%(95%CI 66-100,P<0.001)。

要点

  • 9例重型LAD-I患儿接受marne-cel治疗,无基因治疗相关不良事件,无移植物失败。
  • 输注后1年无HSCT生存率100%(95%CI 66-100,P<0.001)。
  • 输注后90天至24个月感染相关住院年化发生率较输注前降低74.45%。

核心结论

  • 在本研究中,慢病毒载体转导的自体CD34+造血干细胞移植成功治疗了重型LAD-I。

研究设计与样本

  • 1-2期、多国、开放标签研究,纳入9例重型LAD-I患儿,给予marne-cel(含人ITGB2的自失活慢病毒载体转导的自体CD34+造血干细胞)治疗并随访24个月。
  • 2期主要疗效终点为marne-cel输注后至少1年且入组时不足1岁者至2岁时的无同种异体HSCT生存(无HSCT生存),对照无效假设为39%生存率。
  • 还报告了长期随访研究中6例患者的期中数据。

主要发现

  • 观察到与清髓性白消安预处理相关的严重不良事件;未报告归因于基因治疗的不良事件;无患者发生移植物失败。
  • 输注后1年无HSCT生存率为100%(95%置信区间[CI] 66-100,P<0.001)。
  • 所有入组时不足1岁的患者均存活至2岁以上。
  • 与LAD-I相关的治疗前中性粒细胞增多和皮肤异常消退。
  • 植活后90天至marne-cel输注后24个月,感染相关住院年化发生率较输注前降低74.45%,迁延性感染相关住院年化发生率降低81.95%,预设严重感染年化发生率降低84.90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The β2 common integrin subunit CD18 is essential for leukocyte-endothelial adhesion and extravasation to inflamed or infected tissue. Damaging variants in ITGB2, which encodes CD18, cause leukocyte adhesion deficiency type I (LAD-I), an inborn error of immunity that leads to frequent life-threatening infections and a high risk of death among affected children. Allogeneic hematopoietic stem-cell transplantation (HSCT) represents a curative treatment but is limited by donor availability, a high incidence of graft-versus-host disease, and graft failure. METHODS: In a phase 1-2, multinational, open-label study, we enrolled nine children who had severe LAD-I and treated them with marnetegragene-autotemcel (marne-cel), a gene therapy of autologous CD34+ hematopoietic stem cells transduced with a self-inactivating lentiviral vector containing human ITGB2, and followed them for 24 months. The primary efficacy end point of the phase 2 study was survival without allogeneic HSCT (HSCT-free survival) at least 1 year after marne-cel infusion and at 2 years of age among the patients who were younger than 1 year of age at enrollment, tested against a null hypothesis of survival of 39% of the patients. We also report interim data from six patients enrolled in the long-term follow-up study. RESULTS: Serious adverse events related to myeloablative busulfan conditioning were observed. No adverse events attributed to gene therapy were reported. None of the patients had graft failure. HSCT-free survival was 100% (95% confidence interval [CI], 66 to 100) at 1 year after infusion (P<0.001). All the patients who were enrolled at younger than 1 year of age were alive beyond 2 years of age. Pretreatment neutrophilia and skin abnormalities related to LAD-I resolved. The annualized incidence of infection-related hospitalizations beyond 90 days after engraftment through 24 months after marne-cel infusion was 74.45% lower than the incidence before marne-cel infusion, the annualized incidence of prolonged infection-related hospitalizations was 81.95% lower, and the annualized incidence of prespecified serious infections was 84.90% lower. CONCLUSIONS: In this study, lentiviral vector-transduced autologous CD34+ HSCT was successful in treating severe LAD-I. (Funded by Rocket Pharmaceuticals and the California Institute for Regenerative Medicine; ClinicalTrials.gov numbers, NCT03812263 and NCT06282432.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Booth C, Sevilla J, Almarza E, et al. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2025. PMID: 40305711. doi:10.1056/NEJMoa2407376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。